IGFBP4
Insulin-like growth factor-binding protein 4
Protein Summary
IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors. This gene is a member of the insulin-like growth factor binding protein (IGFBP) family and encodes a protein with an IGFBP domain and a thyroglobulin type-I domain. The protein binds both insulin-like growth factors (IGFs) I and II and circulates in the plasma in both glycosylated and non-glycosylated forms. Binding of this protein prolongs the half-life of the IGFs and alters their interaction with cell surface receptors. [provided by RefSeq, Jul 2008]
- ENST00000269593
- ENSP00000269593
- ENSG00000141753
- IBP4
- BP-4
- IBP4
- IGFBP-4
- HT29-IGFBP
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
transcription factor perturbation | 0.99 | ||
PubMedID | 0.95 | ||
protein domain | 0.92 | ||
gene perturbation | 0.85 | ||
transcription factor binding site profile | 0.82 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 344.1 (req: < 5)
Gene RIFs: 62 (req: <= 3)
Antibodies: 616 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 344.1 (req: >= 5)
Gene RIFs: 62 (req: > 3)
Antibodies: 616 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 16
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 2
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0